徐兵河，1958年生，籍貫湖北，腫瘤內科學家，腫瘤醫院主任醫師，博士生導師。1977年考入湖北醫科大學（現武漢大學）醫學專業，1982年獲得學士學位。1984年在中國協和醫科大學腫瘤學專業攻讀碩士學位，從事腫瘤藥物作用機制研究。1996年在中國協和醫科大學腫瘤學專業攻讀博士學位，從事腫瘤藥物臨床研究。1991年進入美國邁阿密大學醫學院進行博士后研究工作，主要研究腫瘤多藥耐藥機制及其逆轉。 1994年為副主任醫師，1998年破格晉升主任醫師，2021年當選中國工程院院士。

長期致力于腫瘤內科臨床和相關基礎研究，重點是乳腺癌的應用基礎、臨床及轉化等關鍵技術研究與抗腫瘤新藥研發。

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

<span id="4thkr"></span>

1. Binghe Xu#*, Qingyuan Zhang, Pin Zhang,Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Yongmei Yin, Yanxia Shi, Yueyin Pan, Yongsheng Wang, Weimin Xie, Min Yan, Yunjiang Liu, Ping Yan, Fei Wu, Xiaoyu Zhu, and Jianjun Zou. Dalpiciclib or placebo plus fulvestrant in pretreated hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 study. 2021,Nature Medicine, 7(11): 1904-1910. (IF 55.4, PIII)

2.Ying Fan#,Tao Sun, Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Zhongsheng Tong, Shusen Wang, Yang Luo, Yuee Teng, Xiaojia Wang, Shu Wang,Qiang Liu, ifeng Feng, Kunwei Shen, Yanqiu Song,Jiayu Wang, Fei Ma, Qing Li, Pin Zhang, Binghe Xu*. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators A Phase 2 Randomized Clinical Trial. JAMA Oncol, 2021, 7(10): E1-E7. (IF 31.7)

3.Yuanyuan Zhang#, Hongyan Chen#, Hongnan Mo#, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu*, Fei Ma*, Zemin Zhang*, Zhihua Liu*. Single-cell analyses reveal key immune cell subsets associated with response to PDL1 blockade in triple negative breast cancer. Cancer Cell, 2021,39: 1-13. (IF 31.7)

4.Binghe Xu#*, Min Yan#, Fei Ma#, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu,Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, and Jianjun Zou. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021, 22(3)：351-360. (IF 41.3, PIII, R)

5.B. Xu#*, T. Sun#, Q Zhang#, P zhang#, Z Yuan, X Wang, S Cui, Y Teng, X-C Hu, J Yang, H Pan, Z Tong, H Li, Q Yao,Y Wang, Y Yin, P Sun, H Zheng, J Cheng, J Lu, B Zhang, C Geng, J Liu, K Shen, S Yu, H Li, L Tang, R Qiu. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.2021, Ann Oncol, 32(2):218-228. (IF 32.9, PIII)

6.Fei Ma#, Quchang Ouyang, Wei Li, Zefei Jiang, Zhongsheng Tong, Yunjiang Liu, Huiping Li,Shiying Yu, Jifeng Feng, Shusen Wang,Xichun Hu, Jianjun Zou, Xiaoyu Zhu, Binghe Xu*. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.2019, J Clin Oncol, 37(29): 2610-2619. (IF 26.3, C100, ESI)

7.Qiao Li#, Xiuwen Guan#, Shanshan Chen, Zongbi Yi, Bo Lan; Puyuan Xing; Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, Jianjun Zou, Xiaoyu Zhu, Fei Ma, Binghe Xu*. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.2019,Clin Cancer Res, 25(17):5212-5220. (IF: 10.107)

8.Fei Ma#, Qiao Li#, Shanshan Chen, Wenjie Zhu, Ying Fan, Jiayu Wang, Yang Luo, Puyuan Xing, Bo Lan, Meiying Li, Zongbi Yi, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu*. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human EGFR2-Positive Metastatic Breast Cancer. 2017, J Clin Oncol, 35(27): 310-316. (IF 24.0, C100)

9.Pin Zhang#, Tao Sun; Qingyuan Zhang; Zhongyu Yuan; Zefei Jiang,; Xiao Jia Wang, Shude Cui ,Yuee Teng, Xi-Chun Hu, Junlan Yang, Hongming Pan, Zhongsheng Tong, Huiping Li, Qiang Yao, Yongshen Wang, Yongmei Yin, Ping Sun, Hong Zheng, Jing Cheng,; Jinsong Lu, Baochun Zhang,Cuizhi Geng, Jian Liu, Roujun Peng, Min Yan, Shaohua Zhang, Jian Huang, Li Tang, Rongguo Qiu, Binghe Xu*. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes. 2017, 17(3):357-366. Lancet Oncol (IF 36.4, PIII)

10.Nadia Harbeck#, Chiun-Sheng Huang, Sara Hurvitz, Dah-Cherng Yeh, Zhimin Shao, Seock-Ah Im, Kyung Hae Jung, Kunwei Shen, Jungsil Ro, Jacek Jassem, Qingyuan Zhang, Young-Hyuck Im, Marek Wojtukiewicz, Qiang Sun, Shin-Cheh Chen, Rainer-Georg Goeldner, Martina Uttenreuther-Fischer, Binghe Xu*, Martine Piccart-Gebhart. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer.  2016, Lancet Oncol, 17 (3):357-366. (IF 33.9, PIII)